Antiphospholipid Antibody Syndrome (APLA / APS) - A Complete Clinical Reference for Gynecologists

1. DEFINITION

• Persistently positive antiphospholipid antibodies (aPL) in the circulation, AND
• At least one clinical manifestation: vascular thrombosis (arterial, venous, or small vessel) OR obstetric morbidity

• Primary APS - no associated autoimmune disease (30-55% of cases)
• Secondary APS - associated with another autoimmune condition, most commonly Systemic Lupus Erythematosus (SLE)

• Creasy & Resnik's Maternal-Fetal Medicine, p. 1280

2. THE THREE KEY ANTIBODIES (aPL Panel)

• LA is the MOST SPECIFIC antibody for APS - a large cohort study found LA (but not other aPL) was independently associated with adverse pregnancy outcomes
• Being triple positive (LA + aCL + aβ2GPI) carries the HIGHEST risk of obstetric and thrombotic complications
• Positive results may be transient (especially after infections like HIV, Hepatitis C) - must confirm 12 weeks later
• LA is a misnomer: patients need not have lupus, and the patient is not actually anticoagulated - it interferes with phospholipid-dependent clotting assays in vitro, making clotting time appear prolonged

• Creasy & Resnik's Maternal-Fetal Medicine, p. 1279-1280

3. REVISED CLASSIFICATION CRITERIA (Sapporo/Sydney Criteria)

CLINICAL CRITERIA

• One or more episodes of arterial, venous, or small-vessel thrombosis in any tissue or organ, confirmed by objective validated criteria (imaging or histopathology)

1. ≥1 unexplained fetal death of a morphologically normal fetus at or beyond 10 weeks' gestation, with normal morphology documented by ultrasound or direct examination
2. ≥1 premature birth of a morphologically normal neonate before 34 weeks' gestation due to:
   • Eclampsia or severe preeclampsia, OR
   • Recognized uteroplacental insufficiency
3. ≥3 unexplained consecutive spontaneous abortions before 10 weeks' gestation, with maternal anatomic/hormonal abnormalities and parental chromosomal causes excluded (euploid losses)

LABORATORY CRITERIA

1. Lupus anticoagulant positive on ≥2 occasions, ≥12 weeks apart
2. Anticardiolipin IgG or IgM in medium or high titer (>40 GPL/MPL, or >99th percentile) on ≥2 occasions, ≥12 weeks apart
3. Anti-β2-glycoprotein-I IgG or IgM (>99th percentile) on ≥2 occasions, ≥12 weeks apart

• Creasy & Resnik's Maternal-Fetal Medicine, p. 1281-1282

4. PATHOGENESIS - WHY IT CAUSES PREGNANCY LOSS

1. Procoagulant effects at multiple sites: Inhibition of prothrombin, protein C, annexin V, coagulation factors VII and XII, platelets, tissue factor procoagulant
2. Impaired fibrinolysis: Inhibition of tissue-type plasminogen activator (tPA)
3. Inhibition of mTORC intracellular pathway in endothelium
4. Complement activation on the trophoblast surface - direct placental damage (distinct from the thrombotic mechanism)
5. Uteroplacental thrombosis - decidual vasculopathy, placental infarction

• Brenner & Rector's The Kidney, p. 1465

5. CLINICAL FEATURES RELEVANT TO GYNECOLOGY

Obstetric Manifestations

Non-Obstetric Manifestations (important to recognize)

• Deep vein thrombosis - 32% (most common)
• Thrombocytopenia - 22%
• Livedo reticularis - 20% (mottled skin - look for it!)
• Stroke / TIA - 13% (most common arterial event)
• Pulmonary embolism - 9%
• Fetal loss - 9%
• Also: pulmonary hypertension, cardiac valvular disease (Libman-Sacks endocarditis), memory disturbances, renal thrombotic microangiopathy

• Creasy & Resnik's Maternal-Fetal Medicine, p. 1281-1282

6. WHO TO TEST? - SCREENING INDICATIONS IN GYNECOLOGY

1. Recurrent Pregnancy Loss (RPL) - ≥2-3 pregnancy losses
2. Unexplained fetal death at ≥10 weeks
3. Early/severe preeclampsia (<34 weeks)
4. Unexplained IUGR / placental insufficiency
5. Unexplained VTE at any age, especially in young women
6. Stroke / TIA in women <50 years (4-5% are aPL-related)
7. SLE patients (25-75% have aPL; check at diagnosis)
8. Unexplained thrombocytopenia
9. Prolonged aPTT on routine workup with no bleeding history

7. MANAGEMENT IN PREGNANCY - THE GYNECOLOGIST'S GUIDE

Risk Stratification Before Treatment

Treatment Protocols

• Therapeutic-dose LMWH + Low-Dose Aspirin (LDA) 75-100 mg/day throughout pregnancy
• Continue anticoagulation 6-12 weeks postpartum (high risk of postpartum VTE)
• Consider switch to warfarin postpartum (warfarin safe in breastfeeding)

• Prophylactic-dose LMWH + LDA 75-100 mg/day during pregnancy
• Continue for 6-12 weeks postpartum
• Hydroxychloroquine 200-400 mg/day - now conditionally recommended as an add-on during pregnancy (improves live birth rates, reduces aPL titers)

• Evidence is limited
• Individualized management - often LDA alone
• Heparin alone does NOT improve live birth rate in unexplained RPL without confirmed APS

Key Points on Heparin + LDA Evidence

• Four of six RCTs showed combination heparin + LDA gives higher live birth rates vs LDA alone
• Meta-analyses and Cochrane reviews support this for confirmed APS
• However, most trial populations are heterogeneous and include women who would NOT meet strict current APS criteria
• Do NOT apply APS treatment to unconfirmed cases - over-diagnosis and over-treatment is a real problem

• Creasy & Resnik's Maternal-Fetal Medicine, p. 984-985

8. IMPORTANT DRUG NOTES FOR OBSTETRIC APS

9. ANTENATAL MONITORING IN APS PREGNANCY

• Detailed anatomy scan at 18-20 weeks
• Serial growth scans from 28 weeks (every 2-4 weeks)
• Umbilical artery Doppler from 24-28 weeks
• Middle cerebral artery Doppler if growth restriction suspected
• Non-stress tests / Biophysical profile from 28-32 weeks, more frequent in high risk
• Watch for early signs of preeclampsia (BP monitoring each visit, urine protein)
• Measure aPL titers at booking (do NOT repeat routinely in pregnancy - use for risk stratification only)

10. POSTPARTUM CONSIDERATIONS

• High-risk period for thrombosis: Risk does NOT end at delivery
• Continue anticoagulation 6-12 weeks postpartum minimum
• Screen for postpartum depression/anxiety (chronic autoimmune disease burden)
• Oral contraceptives: COMBINED OCP is CONTRAINDICATED in APS (dramatically increases thrombotic risk - the "second hit"); use progesterone-only methods or barrier methods
• Future pregnancy counseling: Counsel about recurrence risks; plan next pregnancy in advance with hematologist/rheumatologist
• Confirm diagnosis at 12 weeks postpartum if tests were first done in pregnancy (to avoid false positives from transient antibodies)

11. CATASTROPHIC APS (CAPS) - RARE BUT LIFE-THREATENING

• Also called "Asherson's Syndrome"
• Affects <1% of APS patients but mortality ~50%
• Multiple organ thromboses within days/weeks, affecting ≥3 organs/tissues simultaneously
• Small-vessel thrombosis predominates
• Triggers: Surgery, infection, withdrawal of anticoagulation, pregnancy complications
• Treatment: Triple therapy - anticoagulation + corticosteroids + IVIG or plasmapheresis

12. QUICK SUMMARY TABLE - CLINICALLY CRITICAL POINTS

Recent Evidence (2025)

• Murvai et al. (2025) - Systematic review in BMC Pregnancy Childbirth confirms current management principles and highlights molecular mechanisms of obstetric APS [PMID: 40128683]
• Khalmirzaeva et al. (2025) - Systematic review on molecular mechanisms of obstetric APS, emphasizing the role of complement activation and β2GPI pathways [PMID: 40884378]

• Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice, Chapters 41 and 53
• Brenner and Rector's The Kidney, 2-Volume Set, Chapter on APS
• Revised Classification Criteria (Sapporo/Sydney Criteria) as cited in Creasy & Resnik

Hydroxychloroquine (HCQ) in APLA Syndrome - Role, Mechanisms, and Newer Drugs

PART 1: HYDROXYCHLOROQUINE (HCQ) IN APS

1. What is Hydroxychloroquine?

• Dose in APS: 200-400 mg/day (never exceed 5 mg/kg actual body weight/day due to retinal toxicity)
• Pregnancy dose: 200-400 mg/day (safe, crosses placenta but no teratogenicity at standard doses)

2. Mechanisms of Action in APS - WHY It Works

A. Antithrombotic / Antiplatelet Effects

• Inhibits platelet aggregation and release of arachidonic acid from platelet membranes
• Reduces TXA2-mediated platelet activation
• Decreases expression of glycoprotein IIb/IIIa (fibrinogen receptor) on platelets
• Reduces platelet-neutrophil aggregate formation

B. Disruption of aPL Antibody Binding

• Binds sialic acid residues on cell membranes (including trophoblasts and endothelium), directly blocking antiphospholipid antibody binding to cell surfaces
• Raises intracellular and extracellular pH in lysosomes and endosomes - this interferes with aPL-β2GPI complex formation and disrupts Toll-like receptor (TLR) 7 and 9 signaling (which drives aPL production)
• Blocks beta-2 glycoprotein I (β2GPI) from binding to phospholipids on trophoblast surfaces - this is a key mechanism protecting the placenta

C. Immunomodulatory Effects

• Inhibits lysosomal function: impairs antigen processing and presentation
• Blocks TLR 7/9 signaling: reduces innate immune activation and type I interferon production
• Inhibits NADPH-mediated oxidative stress and autophagy dysregulation
• Reduces B-cell activation and aPL antibody titers over time
• Reduces complement activation on trophoblast surface (key in APS fetal loss)

D. Endothelial Protective Effects

• Reduces endothelial cell activation and adhesion molecule (ICAM-1, VCAM-1) expression
• Protects trophoblast from aPL-induced apoptosis and dysfunction (recent 2025 data: autophagy regulation pathway) [PMID: 40393103]
• S-hydroxychloroquine (a stereoisomer) specifically prevents aPL-β2GPI thrombogenic complex formation [PMID: 40120554]

E. Lipid-Lowering Effects

• Improves lipid profile (reduces LDL, triglycerides) - reduces an additional cardiovascular risk factor in APS

Creasy & Resnik's Maternal-Fetal Medicine; Katzung's Basic & Clinical Pharmacology, 16th Ed.; [PMID: 37741812]; [PMID: 40071459]

3. Evidence for HCQ in APS

In NON-PREGNANT APS (Thrombotic APS):

• Reduces incidence of thrombosis in lupus patients with aPL antibodies
• Long-term HCQ reduces aPL antibody levels (including LA, aCL, aβ2GPI titers) in primary APS [cited in Comprehensive Clinical Nephrology, 7th Ed.]
• Washington Manual of Internal Medicine: "HCQ reduces incidence of thrombosis in lupus patients with antiphospholipid antibody syndrome"
• Now considered a standard add-on in secondary APS (with SLE), and conditionally used in recurrent thrombotic primary APS

In OBSTETRIC APS - The Key Evidence:

4. When to Use HCQ in APS - Current Indications

5. Safety of HCQ in Pregnancy

• Does NOT cause teratogenicity at standard doses (≤400 mg/day / ≤5 mg/kg/day) - confirmed by large cohort studies and international guidelines
• Crosses the placenta - fetal drug levels are measurable, but no consistent association with congenital malformations
• Breastfeeding: Safe (low levels in breast milk)
• DO NOT stop HCQ in SLE/APS patients who become pregnant - abrupt discontinuation causes disease flares and worse outcomes
• Monitor: HCQ blood levels during pregnancy may fall due to increased volume of distribution - subtherapeutic levels are now recognized as a risk factor for flares and adverse outcomes [PMID: 40930382]

• Retinal toxicity (rare at ≤5 mg/kg/day, but baseline ophthalmology exam + annual exam if >5 years of use)
• QT prolongation (monitor ECG in at-risk patients, avoid with other QT-prolonging drugs)
• Hypoglycemia (especially in diabetic patients)
• Nausea, GI upset (take with food)

6. Practical Dosing Guide

PART 2: NEWER / EMERGING DRUGS IN APS

1. Direct Oral Anticoagulants (DOACs) - The Critical Warning

KEY FINDING: DOACs are INFERIOR to Warfarin in HIGH-RISK APS

• 4 RCTs, 472 patients (TRAPS, RAPS, DOAC-APS trials, and others)
• DOACs vs VKA (warfarin/acenocoumarol):
  • Arterial thrombosis: OR 5.43 (95% CI 1.87-15.75) - nearly 5-fold higher risk with DOACs
  • Composite of arterial events + VTE: OR 4.46 (95% CI 1.12-17.84)
  • VTE alone: OR 1.20 (NS) - no significant difference for VTE alone
  • Major bleeding: OR 1.02 (NS) - similar bleeding risk

• They target single coagulation factors (Factor Xa or thrombin)
• APS thrombosis involves multiple pathways simultaneously (platelet activation, endothelial dysfunction, complement, neutrophil extracellular traps) - blocking one factor is insufficient
• LA-positive, triple-positive patients are particularly vulnerable to DOAC failure

When DOACs MAY be considered (carefully selected cases):

• Isolated VTE-only APS (venous, no arterial events, no triple positivity)
• Patients who cannot achieve therapeutic INR on warfarin despite optimization
• Patients with major difficulty with INR monitoring
• NEVER in: triple positive APS, prior arterial thrombosis, pregnant women (absolutely contraindicated)

• VKA (warfarin, target INR 2-3) remains the standard of care for thrombotic APS
• DOACs: NOT recommended in triple-positive APS or APS with prior arterial events
• "Vitamin K antagonists remain the mainstay...and appear superior to DOACs" - BMJ 2023 [PMID: 36849186]

2. Rituximab (Anti-CD20 Monoclonal Antibody)

• Used for refractory thrombocytopenia in APS
• Used in CAPS (Catastrophic APS) as rescue therapy
• Case series and cohort data suggest reduction in aPL titers and clinical improvement in refractory cases
• No large RCTs yet - used under expert supervision
• NOT safe in pregnancy - avoid; may cross placenta and cause neonatal B-cell depletion

3. Eculizumab (Anti-C5 Complement Inhibitor)

• Catastrophic APS: most evidence here - eculizumab has been effective in recurrent CAPS (including one case report cited in Goldman-Cecil Medicine)
• Growing interest as complement plays a critical role in both thrombotic and obstetric APS mechanisms
• Very expensive; used only in life-threatening/refractory situations
• Evidence mostly from case reports and small series

4. Belimumab (Anti-BLYS/BAFF)

5. Sirolimus (mTOR Inhibitor)

6. Statins (Hydroxymethylglutaryl-CoA Reductase Inhibitors)

• Reduce endothelial activation and thromboinflammation
• Decrease adhesion molecule expression (VCAM-1, ICAM-1)
• Reduce complement deposition on endothelium
• Improve lipid profile (co-risk factor in APS)

7. IVIG (Intravenous Immunoglobulin)

• Fc receptor blockade
• Anti-idiotype antibodies that neutralize aPL
• Complement inhibition
• Blocks platelet-endothelial interactions

• Used in refractory obstetric APS (added to heparin + aspirin ± HCQ)
• CAPS treatment: triple therapy - anticoagulation + steroids + IVIG or plasma exchange
• Case series suggest benefit in refractory cases
• Expensive; typically used when standard therapy fails

8. Low-dose Prednisolone / Glucocorticoids

• Used historically in obstetric APS, but evidence from RCTs showed no benefit over heparin + aspirin and increased maternal complications (gestational diabetes, hypertension, preterm birth)
• Current role: mainly in CAPS (high-dose IV methylprednisolone) and SLE-APS flares
• NOT routinely recommended in obstetric APS

SUMMARY TABLE: Drug Landscape in APS (2025-2026)

CLINICAL TAKE-HOME POINTS FOR GYNECOLOGISTS

1. Add HCQ to heparin + aspirin in any obstetric APS patient who fails standard treatment (refractory obstetric APS) - the 2025 meta-analysis shows a dramatic improvement in live birth rates and halving of complication rates.
2. Do NOT use DOACs in high-risk APS - particularly triple-positive patients and any woman with prior arterial thrombosis - the evidence is unequivocal: 5-fold increase in arterial thrombotic events.
3. HCQ is safe in pregnancy at ≤400 mg/day - it should not be stopped when planning pregnancy or during pregnancy.
4. Monitor HCQ blood levels in pregnant APS patients - subtherapeutic levels during pregnancy predict worse outcomes (practical pearl for follow-up).
5. Eculizumab is the go-to rescue for catastrophic APS - liaise immediately with hematology/rheumatology if CAPS is suspected.
6. HCQ reduces aPL titers over time - this means long-term use may actually modify the disease, not just suppress symptoms.

• Creasy & Resnik's Maternal-Fetal Medicine, Chapters 41 & 53
• Goldman-Cecil Medicine, International Ed., Chapter on Coagulation Disorders
• Katzung's Basic & Clinical Pharmacology, 16th Ed., Ch. 36
• Washington Manual of Medical Therapeutics
• Berman et al. (2025) RMD Open [PMID: 40866107] - Systematic Review & Meta-Analysis: HCQ in APS pregnancy
• Khairani et al. (2023) JACC [PMID: 36328154] - Meta-analysis: DOACs vs VKA in APS
• Knight, Branch, Ortel (2023) BMJ [PMID: 36849186] - Advances in APS management
• Fierro et al. (2024) Rheumatol Int [PMID: 37741812] - HCQ in refractory obstetric APS
• Saleh et al. (2026) AJOG [PMID: 40930382] - HCQ in aPL-positive pregnancies
• Depietri et al. (2025) Cardiovasc Drugs Ther [PMID: 37572208] - State of the art APS management